MIRA Pharmaceuticals, Inc. - Common Stock (NQ:MIRA)

MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review

Thursday's session: gap up and gap down stocks ↗

October 01, 2026

Via Chartmill

Performance

52-Week Range 65.5% below 52-week high

0.6195

0.6052W Low 1.7952W High

1 Week 15.1% below 1-week high

0.601W Low 0.731W High

MIRA Pharmaceuticals, Inc. - Common Stock (MIRA) traded between $0.60 and $1.79 over the past 52 weeks and last traded at $0.62, 65.5% below its 52-week high. Over the past week it ranged between $0.60 and $0.73.

Past 12 Months

-3.5%

-26.2%

-29.8%

-39.3%

-58.4%

-58.7%

1W -$0.02

1M -$0.22

3M -$0.26

6M -$0.40

YTD -$0.87

1Y -$0.88

MIRA was -58.7% over the past year, -39.3% over six months, -58.4% year to date, -3.5% in the last week.

12 Months vs Market

MIRA

-58.7%

DIA

+10.4%

SPY

+12.2%

QQQ

+14.1%

IWM

+10.6%

Over the past 12 months MIRA returned -58.7% versus DIA (Dow) +10.4%, SPY (S&P 500) +12.2%, QQQ (Nasdaq 100) +14.1% and IWM (Russell 2000) +10.6%.

Volume & Liquidity 0.18× 3-mo avg

Today 106,231 3-mo avg 587.4K

82.6K

114.4K

587.4K

349.1K

YTD

275.6K

283.5K

MIRA most recently traded 106,231 shares against a 3-month average daily volume of 587.4K.

More News

September 17, 2026

Why Is MIRA Pharmaceuticals Stock Gaining Tuesday? ↗

September 01, 2026

Via Benzinga

MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND

September 01, 2026

MIRA Reports Positive 7-Day Dog Study Results for SKNY-1

August 06, 2026

MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies

July 30, 2026

MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain

July 10, 2026

MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction

July 06, 2026

MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC

June 25, 2026

MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy

June 17, 2026

MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1

June 04, 2026

MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN

May 27, 2026

MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2

May 14, 2026

MIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addiction Drug Candidate

May 13, 2026

MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies

Wondering what's happening in today's after-hours session? ↗

April 01, 2026

Via Chartmill

What's Going On With MIRA Pharma Stock Tuesday? ↗

March 24, 2026

Via Benzinga

March 23, 2026

MIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2

March 04, 2026

MIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase 1 Clinical Study as Company Prepares for Phase 2a Study

February 03, 2026

MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication

12 Health Care Stocks Moving In Monday's After-Market Session ↗

November 10, 2025

Via Benzinga

October 24, 2025